Treatment for RA Patients Intolerant to Methotrexate

Primary Alternative DMARDs

The European League Against Rheumatism (EULAR) guidelines recommend leflunomide or sulfasalazine as first-line alternative therapy for rheumatoid arthritis patients intolerant to methotrexate, with injectable gold as a third option 1, 2, 3
Leflunomide is a preferred first alternative with an efficacy profile similar to methotrexate 4
Sulfasalazine is equally recommended as a first-line alternative 1, 2, 3
Injectable gold is a third option with high-level evidence support 1, 5

For patients with moderate-to-high disease activity who fail to respond adequately to a single conventional DMARD, triple therapy (sulfasalazine + hydroxychloroquine + the alternative DMARD) is recommended 6

The EULAR guidelines recommend adding a biologic DMARD if treatment target (remission or low disease activity) is not achieved after 3-6 months of optimized conventional DMARD therapy 1, 3, 7
First-line biologic options include TNF inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) combined with the alternative DMARD 3, 7
Abatacept, tocilizumab, or rituximab are alternative biologic options 3, 7

Disease activity should be assessed every 1-3 months during active disease 3, 7
If no improvement by 3 months, therapy should be adjusted 3, 7
If treatment target is not reached by 6 months, therapy must be changed 3, 7
Standardized measures such as SDAI >11 or CDAI >10 indicate the need for treatment intensification 6, 7

Low-dose glucocorticoids (≤10 mg/day prednisone equivalent) should be added when starting alternative DMARDs in patients with moderate-to-high disease activity 1, 3, 7
Glucocorticoids should be tapered as rapidly as clinically feasible, ideally within 3-6 months 1, 3, 7

DMARD initiation should not be delayed - start alternative DMARD immediately upon confirming methotrexate intolerance 1, 3, 7
Biologics should not be used as monotherapy - always combine biologics with a conventional DMARD when possible for superior efficacy 3, 7

For patients with liver cirrhosis, rituximab is preferred; avoid most biologics in Child-Pugh Class B or higher 8
For patients with heart failure, TNF inhibitors should be avoided; prefer non-TNF biologics or targeted synthetic DMARDs 4
For patients with hepatitis B, consider prophylactic antiviral therapy if using rituximab 4
Biomarker-guided selection can be used to predict response to biologic therapy, such as positive RF, anti-CCP, or elevated IgG for rituximab 6, 4